Choreo LLC Sells 322 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Choreo LLC lessened its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 5.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 5,173 shares of the medical research company’s stock after selling 322 shares during the quarter. Choreo LLC’s holdings in IQVIA were worth $1,021,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. FMR LLC increased its stake in shares of IQVIA by 38.7% in the third quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock worth $684,213,000 after buying an additional 804,963 shares during the period. JPMorgan Chase & Co. increased its position in shares of IQVIA by 46.2% in the third quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock valued at $437,378,000 after acquiring an additional 583,396 shares during the period. Impax Asset Management Group plc raised its stake in shares of IQVIA by 9.7% during the third quarter. Impax Asset Management Group plc now owns 1,793,010 shares of the medical research company’s stock valued at $423,885,000 after acquiring an additional 157,809 shares during the last quarter. Nordea Investment Management AB grew its stake in shares of IQVIA by 47.4% in the fourth quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock worth $277,908,000 after purchasing an additional 452,029 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in IQVIA by 3.4% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,226,083 shares of the medical research company’s stock valued at $290,545,000 after purchasing an additional 39,772 shares during the period. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other IQVIA news, Director John G. Danhakl acquired 1,275 shares of IQVIA stock in a transaction that occurred on Tuesday, December 3rd. The stock was bought at an average cost of $200.58 per share, for a total transaction of $255,739.50. Following the acquisition, the director now owns 1,275 shares of the company’s stock, valued at $255,739.50. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 1.60% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the company. Truist Financial cut their price objective on IQVIA from $265.00 to $261.00 and set a “buy” rating on the stock in a research report on Thursday, December 12th. BTIG Research downgraded shares of IQVIA from a “buy” rating to a “neutral” rating in a research report on Monday, February 3rd. William Blair reaffirmed an “outperform” rating on shares of IQVIA in a research report on Wednesday, December 11th. Royal Bank of Canada reiterated an “outperform” rating and set a $270.00 price target on shares of IQVIA in a research report on Wednesday, December 11th. Finally, Stephens assumed coverage on shares of IQVIA in a report on Friday, December 20th. They issued an “overweight” rating and a $250.00 price objective for the company. Five equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $252.39.

IQVIA Stock Performance

Shares of IQV stock opened at $208.13 on Monday. The company has a market capitalization of $37.78 billion, a price-to-earnings ratio of 27.75, a price-to-earnings-growth ratio of 2.25 and a beta of 1.48. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.81 and a current ratio of 0.84. IQVIA Holdings Inc. has a one year low of $187.62 and a one year high of $261.73. The company’s 50-day moving average is $200.67 and its 200 day moving average is $219.40.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Sell-side analysts expect that IQVIA Holdings Inc. will post 10.81 EPS for the current fiscal year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.